secwatch.observer — SEC 8-K summary
======================================

Issuer:     Processa Pharmaceuticals, Inc. (PCSA)
CIK:        0001533743
Form:       8-K
Filed at:   2022-11-08T23:59:59+00:00
Accession:  0001493152-22-030944
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Processa: PCS12852 Phase 2A improves gastric emptying (p<0.10); nine-month net loss $14.4M
--------------------------------------------------------------------------------

- PCS12852 Phase 2A: GEBT showed gastric emptying improvement for 0.5mg dose vs placebo (p<0.10); mild-to-moderate AEs, no serious events.
- Net loss for nine months ended Sep 30, 2022: $14.4M ($0.90/share) vs $8.2M ($0.54/share) YoY.
- Cash at Sep 30, 2022: $9.1M; expected to fund operations into Q3 2023.
- R&D expenses rose to $8.3M (up $3.5M) due to ongoing clinical trials; G&A $6.1M (up from $3.4M).
- Plans: Phase 2B trial for PCS12852 in 2023; NGC (PCS6422+capecitabine) Phase 2B planned after FDA meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1533743/000149315222030944/0001493152-22-030944-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1533743/000149315222030944/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-030944

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer